全文获取类型
收费全文 | 177977篇 |
免费 | 47859篇 |
国内免费 | 2322篇 |
专业分类
耳鼻咽喉 | 2211篇 |
儿科学 | 6654篇 |
妇产科学 | 1554篇 |
基础医学 | 33440篇 |
口腔科学 | 7507篇 |
临床医学 | 19222篇 |
内科学 | 36506篇 |
皮肤病学 | 5463篇 |
神经病学 | 23121篇 |
特种医学 | 6927篇 |
外国民族医学 | 13篇 |
外科学 | 20705篇 |
综合类 | 7595篇 |
现状与发展 | 10篇 |
一般理论 | 10篇 |
预防医学 | 13124篇 |
眼科学 | 2583篇 |
药学 | 19994篇 |
18篇 | |
中国医学 | 5316篇 |
肿瘤学 | 16185篇 |
出版年
2023年 | 1027篇 |
2022年 | 1763篇 |
2021年 | 3978篇 |
2020年 | 8163篇 |
2019年 | 14076篇 |
2018年 | 13546篇 |
2017年 | 14296篇 |
2016年 | 13251篇 |
2015年 | 13321篇 |
2014年 | 14475篇 |
2013年 | 15410篇 |
2012年 | 13911篇 |
2011年 | 14431篇 |
2010年 | 12475篇 |
2009年 | 8411篇 |
2008年 | 8831篇 |
2007年 | 7094篇 |
2006年 | 6460篇 |
2005年 | 5963篇 |
2004年 | 5649篇 |
2003年 | 5131篇 |
2002年 | 4636篇 |
2001年 | 3696篇 |
2000年 | 2315篇 |
1999年 | 1210篇 |
1998年 | 834篇 |
1997年 | 749篇 |
1996年 | 655篇 |
1995年 | 573篇 |
1994年 | 496篇 |
1993年 | 471篇 |
1992年 | 426篇 |
1991年 | 395篇 |
1990年 | 337篇 |
1989年 | 282篇 |
1988年 | 272篇 |
1986年 | 212篇 |
1985年 | 889篇 |
1984年 | 1147篇 |
1983年 | 910篇 |
1982年 | 1037篇 |
1981年 | 967篇 |
1980年 | 725篇 |
1979年 | 696篇 |
1978年 | 496篇 |
1977年 | 389篇 |
1976年 | 447篇 |
1975年 | 346篇 |
1974年 | 221篇 |
1973年 | 229篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
内生菌由细菌、真菌、古菌和原生生物组成,它们生活在植物的活体组织中,具有丰富的次级代谢产物多样性。人参内生菌在人参的生长发育、次级代谢产物的生成和环境适应等方面均有重要的促进作用,对人参的产量和品质有较大影响。随着人们在微生物领域研究的深入,高通量测序技术已经成为研究植物内生菌的重要方法。文章主要从人参内生菌分离与鉴定研究方法、人参内生菌的多样性、人参内生菌及其次级代谢产物的活性、人参内生菌对宿主的影响等4个方面对人参内生菌近年来的研究进展进行讨论,并对其发展方向提出展望,以期为药用植物内生菌研究和品质改良提供新思路、新方法。 相似文献
2.
3.
Her-Shyong Shiah Nai-Jung Chiang Chia-Chi Lin Chia-Jui Yen Hui-Jen Tsai Shang-Yin Wu Wu-Chou Su Kwang-Yu Chang Ching-Chiung Wang Jang-Yang Chang Li-Tzong Chen 《The oncologist》2021,26(4):e567-e579
Lessons Learned
- SCB01A is a novel microtubule inhibitor with vascular disrupting activity.
- This first‐in‐human study demonstrated SCB01A safety, pharmacokinetics, and preliminary antitumor activity.
- SCB01A is safe and well tolerated in patients with advanced solid malignancies with manageable neurotoxicity.
4.
5.
6.
《Journal of pediatric surgery》2023,58(5):856-861
Background/PurposeA small number of Hirschsprung disease (HD) patients develop inflammatory bowel disease (IBD)-like symptoms after pullthrough surgery. The etiology and pathophysiology of Hirschsprung-associated IBD (HD-IBD) remains unknown. This study aims to further characterize HD-IBD, to identify potential risk factors and to evaluate response to treatment in a large group of patients.MethodsRetrospective study of patients diagnosed with IBD after pullthrough surgery between 2000 and 2021 at 17 institutions. Data regarding clinical presentation and course of HD and IBD were reviewed. Effectiveness of medical therapy for IBD was recorded using a Likert scale.ResultsThere were 55 patients (78% male). 50% (n = 28) had long segment disease. Hirschsprung-associated enterocolitis (HAEC) was reported in 68% (n = 36). Ten patients (18%) had Trisomy 21. IBD was diagnosed after age 5 in 63% (n = 34). IBD presentation consisted of colonic or small bowel inflammation resembling IBD in 69% (n = 38), unexplained or persistent fistula in 18% (n = 10) and unexplained HAEC >5 years old or unresponsive to standard treatment in 13% (n = 7). Biological agents were the most effective (80%) medications. A third of patients required a surgical procedure for IBD.ConclusionMore than half of the patients were diagnosed with HD-IBD after 5 years old. Long segment disease, HAEC after pull through operation and trisomy 21 may represent risk factors for this condition. Investigation for possible IBD should be considered in children with unexplained fistulae, HAEC beyond the age of 5 or unresponsive to standard therapy, and symptoms suggestive of IBD. Biological agents were the most effective medical treatment.Level of EvidenceLevel 4 相似文献
7.
Phoebe Hammer Kevin White Stephanie Mengden Vessy Korcheva Philipp W. Raess 《Journal of cutaneous pathology》2019,46(5):343-346
Cutaneous leiomyomas are rare benign smooth‐muscle tumors. These lesions are distinguished based on their cell of origin and are subclassified as pilar leiomyoma, angioleiomyoma, and genital‐type leiomyoma. Nipple leiomyoma is the least common genital‐type leiomyoma, arising from the dartoic muscle cell of the nipple. Histologic examination of the lesion is necessary for definitive diagnosis, and these uncommon tumors can pose a diagnostic challenge. We describe herein a series of six nipple leiomyomas with a spectrum of histologic appearances. 相似文献
8.
Keiko Goto Yutaka Fujiwara Takeshi Isobe Naoko Chayahara Naomi Kiyota Toru Mukohara Yukari Tsubata Takamasa Hotta Kenji Tamura Noboru Yamamoto Hironobu Minami 《Cancer science》2019,110(6):1987-1994
Although dose reduction of S‐1 is recommended for patients with impaired renal function, dose modification for such patients has not been prospectively evaluated. The aim of the present study was to investigate the pharmacokinetic parameters of 5‐fluorouracil, 5‐chloro‐2,4 dihydroxypyridine and oteracil potassium, and to review the recommended dose modification of S‐1 in patients with renal impairment. We classified patients receiving S‐1 into 4 groups according to their renal function, as measured using the Japanese estimated glomerular filtration rate (eGFR) equation. The daily S‐1 dose was adjusted based on the patient's eGFR and body surface area. Blood samples were collected for pharmacokinetic analysis. A total of 33 patients were enrolled and classified into 4 groups as follows: 10 patients in cohort 1 (eGFR ≥ 80 mL/min/1.73 m2), 10 patients in cohort 2 (eGFR = 50‐79 mL/min/1.73 m2), 10 patients in cohort 3 (eGFR = 30‐49 mL/min/1.73 m2), and 3 patients in cohort 4 (eGFR < 30 mL/min/1.73 m2). Those in cohorts 3 and 4 treated with an adjusted dose of S‐1 showed a similar area under the curve for 5‐fluorouracil (941.9 ± 275.6 and 1043.5 ± 224.8 ng/mL, respectively) compared with cohort 2 (1034.9 ± 414.3 ng/mL). Notably, while there was a statistically significant difference between cohort 1 (689.6 ± 208.8 ng/mL) and 2 (P = 0.0474) treated with an equal dose of S‐1, there was no significant difference observed in the toxicity profiles of the cohorts. In conclusion, dose adjustment of S‐1 in patients with impaired renal function using eGFR is appropriate and safe. 相似文献
9.